An article published by the New York Times outlines how an FDA black box warning for the asthma drug Singulair (montelukast) did little to alert patients to its potential mental health side effects or to dissuade physicians from prescribing it.
An article published by the New York Times outlines how an FDA black box warning for the asthma drug Singulair (montelukast) did little to alert patients to its potential mental health side effects or to dissuade physicians from prescribing it.
Read More
Asthma and allergy drug montelukast (Singulair) can bind to and block a protein produced by the virus SARS-CoV-2 and reduce viral replication.
Read More
“Because of the risk of mental health side effects, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with other medicines,” the FDA said.
Read More
